Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21023137 | 0.96 | CYP3A4 (0.41) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9437255 | 0.89 | EPOR (0.46) | L3MBTL1TSHRKMT2AHTT | |
| SCHEMBL9326820 | 0.88 | L3MBTL1 (0.41) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9326758 | 0.88 | L3MBTL1 (0.41) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9325011 | 0.87 | L3MBTL1 (0.42) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9326166 | 0.86 | L3MBTL1 (0.44) | L3MBTL1MEN1KMT2A | |
| SCHEMBL9326206 | 0.86 | L3MBTL1 (0.42) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9327201 | 0.86 | L3MBTL1 (0.42) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9326236 | 0.86 | L3MBTL1 (0.44) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 | |
| SCHEMBL9775369 | 0.83 | L3MBTL1 (0.47) | L3MBTL1CYP3A4CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149046-B2 | Antibacterial sideromycins | Hsiri Therapeutics, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | Hsiri Therapeutics, LLC | 2019-05-23 | — | — | US | disclosed |
| US-5254724-A | Method for synthesis of desferrioxamine B, analogs and homologs thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 1993-10-19 | — | — | US | disclosed |
| WO-1993016983-A1 | COMPOUNDS USED IN CONTRAST PRODUCTS FOR RADIOGRAPHY | GUERBET S.A. (FR) | 1993-09-02 | — | — | WO | disclosed |
| WO-1993009088-A1 | IMPROVED METHOD FOR SYNTHESIS OF DESFERRIOXAMINE B, ANALOGS AND HOMOLOGS THEREOF | UNIVERSITY OF FLORIDA (US) | 1993-05-13 | — | — | WO | disclosed |
| US-4987253-A | Method for the synthesis of desferrioxamine B and analogs thereof | UNIVERSITY OF FLORIDA (US) | 1991-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149046-B2 | Antibacterial sideromycins | SLC40A1, SFXN1, SLC39A14 | L3MBTL1 1599/4885CYP3A4 3200/4885CYP2C9 3536/4885 |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | SLC40A1, SFXN1, SLC39A14 | L3MBTL1 1599/4885CYP3A4 3200/4885CYP2C9 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.